Autoimmune cytopenias (AIC) are common in chronic lymphocytic leukemia (CLL) and include autoimmune hemolytic anemia (AIHA), immune thrombocytopenia (ITP), and, less commonly, pure red blood cell aplasia (PRCA). It is generally accepted that treatment of CLL-associated AIC should be primarily directed against the autoimmune phenomenon, and CLL-specific therapy is reserved for refractory cases or for patients with additional signs of disease progression 1 .
Ibrutinib, a small-molecule inhibitor of Bruton's tyrosine kinase (BTK) induces durable remissions in patients with CLL 2 . The activity of ibrutinib in CLL-associated AIC is largely unknown, partly due to the exclusion of patients with uncontrolled AIC from the pivotal clinical trials. Recently, episodes of AIHA during ibrutinib treatment have been described 3, 4 , but two different prospective trials reported a low incidence of treatmentemergent AIC (no cases out of 195 patients and 6 cases out of 301 patients, respectively) 5, 6 . Moreover, the successful management of AIHA with ibrutinib, alone or in association with glucocorticoids (GC), has been reported in a few case reports 5, [7] [8] [9] .
We identified 13 patients with CLL who were treated with ibrutinib and had signs of AIC at the time of treatment initiation, and we studied their clinical presentation, PRCA was diagnosed in the presence of anemia without signs of hemolysis and with concomitant absence of erythroid precursors in the bone marrow and blood.
AIC was defined active when it was not controlled with current medical management, controlled when counts were maintained stable but not normalized (or, for AIHA, when hemoglobin was normalized but signs of subclinical hemolysis persisted), and resolved when complete normalization of counts occurred. We defined AIC flare as a sudden reactivation of the autoimmune process after a period of stable peripheral blood counts.
Patient characteristics at the time of ibrutinib initiation are shown in Table 1 and Figure 1 ). In another patient ibrutinib dose was temporarily reduced, and later increased back to 420 mg in association with rituximab and GC. In another patient ibrutinib was held and then restarted at a reduced dose (140 mg QD) after the cytopenia had been controlled with GC and IVIG. One patient had ibrutinib permanently discontinued at the time of the autoimmune flare.
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In 6 out of these 9 patients (67%), treatment was able to stabilize and subsequently resolve the autoimmune process. In the remaining 3 patients, peripheral blood counts stabilized and only mild cytopenia persisted.
Among the cases that followed a different pattern, not manifesting with an AIC flare, patient #2 (Supplemental Figure 2) is particularly interesting. This patient was diagnosed with transfusion-dependent PRCA, unresponsive to cyclosporine treatment.
Improvement in hemoglobin levels and transfusion independency was achieved with ibrutinib in combination with GC, rituximab and IVIG, and was accompanied by the recovery of erythroid precursors in the bone marrow (Supplemental Figure 3 ). Patient #3 also had transfusion-dependent PRCA with laboratory evidence of AIHA, and started ibrutinib while on cyclosporine. Reticulocyte count and erythroid hypoplasia improved during ibrutinib therapy and the patient became transfusion-independent with persistent laboratory evidence of hemolysis.
In the remaining 2 patients (17%), no autoimmune flare was noted, and treatment with ibrutinib alone was sufficient to treat and resolve the autoimmune phenomenon with normalization of the peripheral blood cell counts.
Interestingly, in 3 of the patients with AIHA who responded to treatment with ibrutinib, a sero-conversion to DAT-negativity was observed after 9-12 months on ibrutinib (patients #9, #12, #13).
These heterogeneous clinical scenarios reflect the variable clinical phenotypes of AIC in CLL and the absence of a standard therapy in the era of kinase inhibitors. Based on our experience, most patients were successfully managed by continuation of ibrutinib and temporary addition of a conventional therapy (i.e., GC, IVIG) to target the autoimmune process. Collectively, 9/13 patients (69%) had resolved or controlled AIC with ibrutinib treatment only at the time of last follow-up.
To assess the CLL response to ibrutinib therapy, we used the International Workshop on Chronic Lymphocytic Leukemia-National Cancer Institute guidelines 1 . A persistently elevated lymphocyte count in patients otherwise categorized as in partial response (PR)
was not considered a sign of disease progression (PR with persistent lymphocytosis, PRL) 13 . Nine of 13 patients (69%) responded to the treatment: one patient (8%) had a complete response (CR) unconfirmed by bone marrow biopsy, 5 patients (38%) had a partial response (PR), and 3 patients (23%) achieved PRL. Three patients had stable disease (SD): 1 of these 3 discontinued ibrutinib after 9 months due to lack of response (patient #4), while the other two continued treatment after 4 and 7 months, respectively.
One patient was not evaluable for response due to early discontinuation (patient #11).
Overall, 10 patients (77%) continued on ibrutinib at the time of the data analysis (median follow-up since the start of ibrutinib: 13 months, range 4-36). These data are in line with the notion that the treatment of the underlying CLL is critical for the long-term control of CLL-associated AIC.
The impact of ibrutinib on AIC in CLL is of particular interest because BTK inhibition can have pleiotropic effect on different components of the immune system (reviewed in 14 ).
Ibrutinib also functions as an inhibitor of the IL-2 inducible kinase (ITK) and can promote a shift from Th2-towards Th1-polarized immunity 15 . To gain more insights into plasma cytokines changes during autoimmune flares, we therefore analyzed the plasma concentration of 21 different cytokines in 4 of the patients from our series (Supplemental Methods). The results were overall heterogeneous (Supplemental 
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